Oxford, UK, 6th July 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced encouraging early clinical data from its Hong Kong Phase I study to develop CXD101 in patients suffering from peripheral T-cell lymphoma (PTCL),…
Oxford, April 2nd, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, has worked closely with Oxford University’s Medical Sciences Division to investigate the mechanism of action of zabinostat (previously known as CXD101). The study found…
Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by its Chief Medical Officer, Professor David Kerr, at the WuXi Healthcare Forum 2021. The second annual WuXi Healthcare Forum will…
Oxford, UK, 20 January 2021 – Celleron Therapeutics, the Oxford-based UK company developing novel medicines to treat cancer, today announced that with its Chinese partner, Nuance Biotech Ltd, the company has received approval from the Chinese Center for Drug Evaluation for…
Oxford, November 30, 2020 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announces the formation of a new spin out, SynOx Therapeutics, as a vehicle for the continued development of emactuzumab as an effective treatment for…
Oxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today attended and presented remotely at the opening ceremony of BIO-FORUM 2020…
Oxford, 12th August 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing of a licensing agreement with Roche providing Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab.…
Oxford, UK / Sichuan, China, 15 May 2020 Today marks the launch of the University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer, led by Prof. David Kerr (Radcliffe Department of Medicine, University of Oxford) and Prof. Li Yang…
Oxford, UK, 2nd March 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced that its partner in China, Nuance Biotech Ltd., initiated a Phase Ib/II study in Hong Kong to test CXD101 in patients…
Lack of colitis side effect with CXD101 and nivolumab combination therapy in CAROSELL Phase II clinical trial of MSS CRC patients Oxford, UK, 14 Jan 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, announced today…